Table of Contents
In a heartbreaking turn of events, the ongoing shortage of essential epilepsy medications has left patients vulnerable, with one man paying the ultimate price. David Crompton, a 44-year-old from Leeds, tragically lost his life on December 13 after a fall that led to a cardiac arrest. His death has shed light on a growing crisis that is putting lives at risk across the UK.
A Life Cut Short
David Crompton’s story is a stark reminder of the fragility of life for those living with epilepsy. According to a coroner’s report, his death was linked to his inability to access Tegretol, a critical anti-epileptic medication. The Midway Pharmacy in Pudsey,where he was a regular customer,had reportedly run out of the drug and left him with an “IOU” instead of ensuring he received his prescription.
This wasn’t the first time David had been left without his medication. Earlier in April 2024, he went without Tegretol for nearly 10 days, during which he suffered a fall. The pharmacy’s failure to secure his medication a second time proved fatal. As Kevin McLoughlin, the senior coroner for West Yorkshire, noted in his report, “The evidence given by family members at the inquest was that when the pharmacy was unable to supply the prescribed Tegretol medication, it was left to them to contact othre pharmacies to see if they could obtain it, rather than for the pharmacy to search for supplies.”
A Growing National Crisis
david’s death is not an isolated incident.It highlights a broader issue of medication shortages that has plagued the NHS in recent years. In May 2024, the Department of Health and social Care issued a supply notification for Tegretol 100mg/5ml liquid, acknowledging the shortage.Novartis,the drug’s manufacturer,stated that while some supplies were available,“it may take some time for supply to return to normal levels.”
This shortage is part of a larger trend. In January 2024, reports revealed that the number of medicines in short supply had doubled over two years, putting countless lives in jeopardy. For epilepsy patients, the stakes are particularly high. Missing even a single dose of medication can trigger seizures, leading to severe injuries or, as in David’s case, death.
A Call to Action
clare Pelham, the chief executive of the Epilepsy Society, has been vocal about the urgent need for government intervention. “How can it be the case that sadly someone dies as an inevitable result of a medicines shortage in the UK?” she asked. “We have been warning for months of the worst and most extreme outcome that medication shortages can have for people with epilepsy.”
Pelham emphasized the need for immediate action, quoting Winston Churchill: “We need action this day.” She called for the establishment of a taskforce with strong leadership and accountability, urging Health Secretary Wes Streeting to prioritize the issue.“Charities and people across the pharmaceutical industry and supply chain are only too willing to lend their expertise,” she added. “I hope the government will recognize the importance of acting now.”
What Can Be Done?
The tragic loss of David Crompton underscores the need for systemic changes to prevent such incidents in the future. Here are some actionable steps that could help address the crisis:
- Improved Supply Chain Management: Pharmacies and healthcare providers must work together to ensure patients have uninterrupted access to critical medications.
- Government Intervention: A dedicated taskforce should be established to monitor and address medication shortages, with clear accountability and timelines.
- Patient Advocacy: Families and caregivers should be empowered with resources to navigate shortages and advocate for their loved ones’ needs.
Conclusion
David Crompton’s death is a sobering reminder of the human cost of medication shortages. For epilepsy patients, access to life-saving drugs is not a luxury—it’s a necessity. As the UK grapples with this crisis, it is indeed imperative that all stakeholders—pharmacies, manufacturers, and the government—work together to ensure no one else suffers the same fate. The time for action is now.
What are the primary factors contributing to the shortage of epilepsy medications in the UK?
Interview with Dr. Emily Carter, Pharmacologist and Epilepsy Medication Expert
Conducted by Archyde News Editor, Sarah Thompson
Sarah Thompson (Archyde): Dr. Carter, thank you for joining us today. The tragic death of David Crompton has brought the issue of epilepsy medication shortages into sharp focus. Can you explain why these shortages are happening and how widespread they are?
Dr. Emily carter: Thank you for having me, Sarah. The shortages of epilepsy medications like Tegretol (carbamazepine) and Lamictal (lamotrigine) are part of a broader crisis in the pharmaceutical supply chain. Factors such as manufacturing delays, Brexit-related trade disruptions, and increased global demand have all contributed to this issue. According to recent reports, these shortages are becoming the “new normal,” placing a significant burden on pharmacists and leaving patients vulnerable.
Sarah Thompson: David Crompton’s case highlights the devastating consequences of these shortages. He was unable to access Tegretol, a medication critical to managing his epilepsy. How common is it for patients to face such gaps in their treatment?
Dr. Emily Carter: Unfortunately, David’s story is not unique. Many epilepsy patients across the UK are experiencing similar challenges. epilepsy medications are not interchangeable; patients frequently enough rely on specific drugs to control their seizures. When these medications are unavailable, even for a short period, it can lead to breakthrough seizures, injuries, or, in the worst cases, fatalities. The fact that David’s pharmacy left him with an “IOU” rather of proactively sourcing his medication is deeply concerning and reflects systemic failures.
Sarah Thompson: The coroner’s report noted that David’s family had to search for his medication themselves. Shouldn’t pharmacies be taking more responsibility in these situations?
Dr. Emily Carter: Absolutely. Pharmacies have a duty of care to ensure patients receive their prescribed medications. In cases of shortages, they should be actively reaching out to other pharmacies, wholesalers, or even contacting the prescribing doctor to explore alternatives. Leaving patients or their families to navigate this process is not only unethical but also hazardous. Pharmacies need better systems and support to manage these shortages effectively.
Sarah Thompson: What steps can be taken to address this crisis and prevent further tragedies like David’s?
Dr. Emily Carter: There are several measures that need to be implemented urgently. First, the government and pharmaceutical companies must work together to stabilize the supply chain and prioritize the production of essential medications. Second,pharmacies need clearer guidelines and resources to manage shortages,including better dialog with patients and healthcare providers. we need greater awareness and advocacy to ensure that epilepsy patients are not left behind in these discussions.
Sarah thompson: What message would you like to send to policymakers and the public about this issue?
Dr.Emily Carter: This is a life-and-death issue. Epilepsy patients depend on these medications to live safely and independently. The current shortages are not just an inconvenience—they are a public health crisis. Policymakers must act swiftly to address the root causes of these shortages, and the public must demand accountability. No one should have to suffer or lose their life because they couldn’t access the medication they need.
Sarah Thompson: Thank you, Dr. Carter, for your insights and for shedding light on this critical issue. We hope your expertise will help drive the changes needed to protect epilepsy patients across the UK.
Dr. Emily Carter: Thank you, Sarah. It’s been a pleasure to speak with you, and I hope this conversation sparks the urgent action required to prevent further tragedies.
End of Interview
This interview highlights the urgency of addressing epilepsy medication shortages and underscores the need for systemic changes to protect vulnerable patients. David Crompton’s tragic death serves as a stark reminder of the human cost of this crisis.
